Short Communication

Inhibitory KIR–HLA receptor–ligand mismatch in autologous haematopoietic stem cell transplantation for solid tumour and lymphoma

W Leung1,2,3, R Handgretinger1,2, R Iyengar1, V Turner2, MS Holladay1 and GA Hale1,3

1Department of Hematology-Oncology, St Jude Children’s Research Hospital, Memphis, TN, USA; 2Department of Pathology, St Jude Children’s Research Hospital, Memphis, TN, USA; 3Department of Pediatrics, University of Tennessee Health Science Center, Memphis, TN, USA

Genes that encode killer Ig-like receptors (KIRs) and their HLA class I ligands segregate independently; thus, some individuals may express an inhibitory KIR gene but not its cognate ligand. We hypothesised that these patients with KIR–HLA receptor–ligand mismatch have a low risk of relapse after an autologous haematopoietic stem cell transplantation (HCT). Sixteen consecutive patients with lymphoma or solid tumour were enrolled onto a prospective study. They received high-dose busulphan and melphalan followed by autologous CD133⁺ HCT. We found that 8 of the 16 patients experienced disease progression after autologous HCT, including 5 of the 6 patients (83%) with no inhibitory KIR–HLA mismatch and 3 of the 6 patients (50%) with 1 mismatched pair; none of the 4 (0%) patients with 2 mismatched pairs experienced disease progression. Survival analyses showed that inhibitory KIR–HLA mismatch was the only significant prognostic factor (P = 0.01). The potential applicability of the receptor–ligand mismatch model to autologous HCTs and to patients with lymphoma or solid tumour is clinically significant because of the prevalence of the HCT procedure.

Keywords: natural killer cells; solid tumour; lymphoma; autologous transplantation

Human NK cells are regulated by killer Ig-like receptors (KIRs) that recognise specific groups of HLA class I alleles (Lanier, 2005). Both KIRs and their HLA ligands exhibit tremendous population diversity, and the KIR genes on chromosome 19 and HLA genes on chromosome 6 segregate independently (Hsu et al, 2002; Parham, 2005). Thus, many individuals have an inhibitory KIR gene but not its corresponding ligand, while others may have a certain KIR ligand but not its corresponding KIR (Leung et al, 2004; Parham, 2005).

In corroboration with these genetic findings, we found that the risk of relapse after haploidentical haematopoietic stem cell transplantation (HCT) in patients with haematologic malignancies was best predicted by a model taking into consideration the expression of inhibitory KIRs on the donor NK cells and the absence of corresponding KIR ligands in the recipient’s HLA repertoire (a KIR–HLA receptor–ligand mismatch model) (Leung et al, 2004). For those HCTs in which neither the donor nor the recipient had the cognate ligand for the donor’s inhibitory KIRs, the patients were found to be at low risk of relapse. Indeed, autoreactive NK cell clones, which are KIR2DL2/2DL3⁺, 2DL1⁺, and 3DL1⁺, have been found in healthy donors who lack HLA-Cα*008 (the ligand for KIR2DL2/2DL3), and NK cells from approximately 50% of these individuals were cytotoxic against autologous CD34⁺ cells (Grau et al, 2004). Therefore, it is logical to examine the application of the receptor–ligand mismatch model to autologous HCTs. Because lymphoid leukaemias and solid tumours such as neuroblastoma are susceptible to KIR–HLA mismatched NK cell–mediated lysis (Leung et al, 2004, 2005a), we conducted a prospective study to test the hypothesis that patients with lymphoma or other solid tumour who receive autologous HCT have a low risk of relapse if KIR–HLA mismatch(es) is present.

PATIENTS AND METHODS

Autologous HCT

All patients were enrolled onto an autologous HCT protocol approved by the Institutional Review Board, and the patients or their legal guardians gave the written informed consent. After enrolment, all patients received 10 mcg kg⁻¹ per day G-CSF for 5 days and then underwent leukapheresis for peripheral blood stem cell collection. Apheresis products were selected for CD133⁺ cells by using the CliniMACS system for tumour-cell purging, except for two that had low initial cell count. Conditioning consisted of busulfan (37.5 mg m⁻² per dose every 6 h intravenously for 16 doses) and melphalan (70 mg m⁻² per day for 2 days). After stem cell infusion, all patients received G-CSF, starting 5 days after HCT until ANC was > 3000 mm⁻³ for two consecutive days.
HLA and KIR typing

All samples were HLA typed by DNA methods as previously described (Leung et al, 2004). KIR genotyping was performed by using a genotyping kit from Pel-Freeze (now Dynal Biotech, Invitrogen, Carlsbad, CA, USA) and KIR phenotyping was determined by flow cytometry analysis, as some of the KIRs may not be expressed on the cell surface (Leung et al, 2005b). Thus, a KIR was classified to be positive for a particular patient only if that KIR gene was tested positive by genotyping and was also found to be expressed by NK cells in phenotyping. The natural cytotoxicity of NK cells against K562 cells was determined by a standard europium release assay with a 40:1 (E:T) cell ratio (Leung et al, 2004).

Statistical analysis

The cohort was divided into two risk groups based on the inhibitory KIR–HLA receptor–ligand model and cytotoxicity model, which have been described previously (Leung et al, 2004). Briefly, a patient was classified as being at low risk by using the KIR–HLA receptor–ligand model if at least one of the inhibitory KIR genes expressed on the patient’s NK cells did not recognise any of the HLA molecules in the patient’s HLA ligand repertoire. The patients in the low-risk group were then further categorised by the number of receptor–ligand mismatch pairs. The hypothesis was that a larger number of KIR–HLA mismatch pairs would result in greater antitumour activity (Leung et al, 2004). The cytotoxicity model measured the general cytotoxicity of engrafting NK cells against K562 cells (Leung et al, 2004). The Perugia’s KIR ligand incompatibility model was not used, because all grafts were ligand matched with the recipients by definition (ie, the KIR ligands present in the graft were identical to those in the KIR–HLA mismatch in autologous HCT

Table 1 Characteristics of 16 consecutive patients who underwent autologous HCT and were grouped by their numbers of inhibitory KIR–HLA receptor–ligand mismatch pairs

| Disease    | Indication for HCT | Disease status at the time of HCT | No. of CD133+ cells in the graft (×10³ kg⁻¹) | Natural cytotoxicity (%)a | HLA-Bw | HLA-C | KIR mismatch* | Outcome |
|------------|--------------------|----------------------------------|---------------------------------------------|--------------------------|--------|------|--------------|---------|
| NB         | Stage 4            | VGPR                             | 7.9                                         | 32.0                     | 6/6    | Asn80/Asn80 | 2DL1, 3DL1 | Alive, NED |
| HD         | Relapse            | PR                               | 5.5                                         | 13.1                     | 6/6    | Asn80/Asn80 | 2DL1, 3DL1 | Alive, NED |
| HD         | Relapse            | CR                               | 4.8                                         | 35.0                     | 6/6    | Asn80/Asn80 | 2DL1, 3DL1 | Alive, NED |
| HD         | Relapse            | PR                               | 5.0                                         | 16.8                     | 6/6    | Asn80/Asn80 | 2DL1, 3DL1 | Alive, NED |
| NB         | Stage 4            | VGPR                             | 7.6                                         | 13.5                     | 4/6    | Asn80/Asn80 | 2DL1     | Alive, NED |
| NB         | Relapse            | PR                               | 2.1                                         | ND                       | 6/6    | Asn80/Lys80 | 3DL1     | Alive, NED |
| NHL        | Relapse            | PR                               | 2.2                                         | 31.0                     | 6/6    | Asn80/Lys80 | 3DL1     | Alive, NED |
| NB         | Stage 4            | VGPR                             | 8.0                                         | 15.9                     | 6/6    | Asn80/Asn80 | 3DL1     | Died of PD |
| NHL        | Relapse            | PR                               | 3.9                                         | 15.6                     | 4/6    | Lys80/Lys80 | 2DL3     | Died of PD |
| PNET       | Metastasis         | CR                               | 5.3                                         | 16.5                     | 4/6    | Asn80/Asn80 | 2DL1     | Died of PD |
| DSRCT      | Metastasis         | CR                               | 5.4                                         | 18.4                     | 4/6    | Asn80/Asn80 | None     | Alive, NED |
| NHL        | Relapse            | PR                               | 2.5                                         | ND                       | 4/6    | Asn80/Lys80 | None     | Died of PD |
| ES         | Relapse            | PR                               | 3.8                                         | 26.8                     | 4/6    | Asn80/Lys80 | None     | Died of PD |
| NB         | Stage 4            | VGPR                             | 7.8                                         | 17.7                     | 4/4    | Asn80/Lys80 | None     | Died of PD |
| NB         | Stage 4            | PR                               | 6.0                                         | ND                       | 6/6    | Asn80/Lys80 | None     | Died of PD |
| NB         | Stage 4            | VGPR                             | 8.0                                         | 15.0                     | 4/6    | Asn80/Lys80 | None     | Died of PD |

Abbreviations: CR = complete response; DSRBT = desmoplastic small round cell tumour; ES = Ewing’s sarcoma; HD = Hodgkin’s disease; NB = neuroblastoma; ND = not done; NED = no evidence of disease; NHIL = non-Hodgkin’s lymphoma; PD = progressive disease; PNET = primitive neuroectodermal tumour; PR = partial response; VGPR = very good partial response. *Natural cytotoxicity indicates the specific lysis of K562 cells by blood mononuclear cells post-HCT and is used for the analysis of the cytotoxicity model; KIR–HLA mismatch is determined by using the receptor–ligand model.
was observed in cervical cancer and melanoma (Carrington et al., 2005; Naumova et al., 2005).

DISCUSSION

NK cells in our patients after autologous HCT were primarily derived from stem/progenitor cells, because mature NK cells were depleted in vivo and ex vivo by the myeloablative conditioning and CD133+ cell–selection procedure. During the period of receptor acquisition, subsets of NK cells may express a certain inhibitory KIR with no cognate ligand. Recent studies in healthy mice have demonstrated that NK cells expressing inhibitory receptors with no self-ligands exist (Fernandez et al., 2005; Kim et al., 2005). These cells are hyporesponsive in steady state, because they have not undergone the ‘licensing’ process (Kim et al., 2005; MacDonald, 2005). However, the hyporesponsive state of these ‘unlicensed’ NK cells is not permanent, as they can be activated easily in response to proinflammatory cytokines that activate almost all NK cells during infection (Biron et al., 1999; Kim et al., 2005). Thus, the licensing effect was much less prominent among preactivated NK cells, a finding suggesting that the licensing requirement could be circumvented in specific situations (Kim et al., 2005). The high-dose cytotoxic chemotherapy given to our patients may provide the proinflammatory setting that favours autoreactive NK cells against tumour cells that express high level of activating ligands (Castriconi et al., 2004). Worthy of notice, the other transplant settings in this cohort were also reminiscent of those of our previous haploidentical cohort in which the KIR–HLA receptor–ligand model was first established; namely, NK cells were derived from highly purified stem cells (Leung et al., 2004); mature T cells and B cells were extensively depleted to provide a lymphopenic environment (Prlic et al., 2003; Jamieson et al., 2004); and there was no interference by graft-versus-host disease or its treatment (Lowe et al., 2003; Cooley et al., 2005). All of these factors may contribute significantly to the prominent NK cell effects observed in this study.

The extension of the applicability of the KIR–HLA receptor–ligand model to autologous HCTs is clinically significant, as the number of autologous HCTs performed worldwide annually is twice that of allogeneic HCTs (Center for International Blood and Marrow Transplant Research (CIBMTR) website, 2006). Haploidentical HCTs are performed only in a few centres, whereas autologous HCTs are offered in almost all the transplantation centres. Herein, we demonstrated for the first time that patients with inhibitory KIR–HLA mismatch are at low risk of relapse after autologous HCT. Other novel observation is that the receptor–ligand model may be applicable not only to patients with leukaemia (Leung et al., 2004, Hsu et al., 2005), but also to patients with lymphoma or solid tumour. One limitation of this study is that the number of patients was small for each disease category. Our novel findings, however, should stimulate future studies in other centres and in larger cohorts with uniform primary diseases. If confirmed, these results will have significant implications for prognostication and selection of patients for autologous HCT.

ACKNOWLEDGEMENTS

We thank Angela J McArthur, Ph.D., for scientific editing, and Margaret Swann for secretarial assistance. This work was supported in part by National Institutes of Health grant P30CA21765-24 (to WL), the Assisi Foundation of Memphis (to WL), and the American Lebanese Syrian Associated Charities (ALSAC).

REFERENCES

Allele Frequencies in Worldwide Populations Website (2006) http://www.allelefrequencies.net/Search.Asp Accessed on November 25, 2006
Biron CA, Nguyen KB, Pien GC, Cousens LP, Salazar-Mather TP (1999) Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annu Rev Immunol 17: 189–220
Carrington M, Wang S, Martin MP, Gao X, Schiffman M, Cheng J, Herrero R, Rodriguez AC, Kurman R, Mortel R, Schwartz P, Glass A, Hildesheim A (2005) Hierarchy of resistance to cervical neoplasia mediated by combinations of killer immunoglobulin-like receptor and human leukocyte antigen loci. J Exp Med 201: 1069–1075

Figure 1  Significance of inhibitory KIR–HLA receptor–ligand mismatch. (A) Cumulative incidence (CI) of disease progression in patients with different numbers of receptor–ligand mismatch pairs (P = 0.02). (B) Event-free survival (EFS) of patients with receptor–ligand mismatch and of those with no mismatch (P = 0.01). Progression-free survival was identical to EFS because there was no transplant-related mortality.

Table 2  Risk factor analysis for event-free survival

| Factor                                             | Hazard ratio | 95% CI     | P-value |
|----------------------------------------------------|--------------|------------|---------|
| Receptor–ligand model (match vs mismatch)          | 5.5          | 1.3–24.2   | 0.01    |
| Disease (lymphoma vs other solid tumours)          | 0.9          | 0.1–7.9    | 0.94    |
| Disease status (PR vs CR/VGPR)                     | 1.3          | 0.3–5.3    | 0.71    |
| Cytotoxicity model                                 | 0.9          | 0.7–1.1    | 0.42    |
| Number of CD133+ cells in graft                    | 1.2          | 0.8–1.8    | 0.43    |

Abbreviations: CR = complete response; PR = partial response; VGPR = very good partial response.
Castriconi R, Dondoro A, Corrias MV, Lanino E, Pende D, Moretta L, Bottino C, Moretta A (2004) Natural killer cell-mediated killing of freshly isolated neuroblastoma cells: critical role of DNAX accessory molecule-1-poliovirus receptor interaction. Cancer Res 15: 9180 – 9184

Center for International Blood and Marrow Transplant Research (CIBMTR) (2006) website: http://www.ibmtr.org/infoserv. Accessed on November 25, 2006

Cooley S, McCullar V, Wangen R, Bergemann TL, Spellman S, Weisdorf DJ, Miller JS (2005) KIR reconstitution is altered by T cells in the graft and correlates with clinical outcomes after unrelated donor transplantation. Blood 106: 4370 – 4376

Fernandez NC, Treiner E, Vance RE, Jamieson AM, Lemieux S, Raulet DH (2005) A subset of natural killer cells achieves self-tolerance without expressing inhibitory receptors specific for self-MHC molecules. Blood 105: 4416 – 4423

Grau R, Lang KS, Wernet D, Lang P, Niethammer D, Pusch CM, Handgretinger R (2004) Cytotoxic activity of natural killer cells lacking killer-inhibitory receptors for self-HLA class I molecules against autologous hematopoietic stem cells in healthy individuals. Exp Mol Pathol 76: 90 – 98

Hsu KC, Chida S, Geraghty DE, Dupont B (2002) The killer cell immunoglobulin-like receptor (KIR) genomic region: gene-order, haplotypes and allelic polymorphism. Immunol Rev 190: 40 – 52

Hsu KC, Keever-Taylor CA, Wilton A, Pinto C, Heller G, Arkun K, O’Reilly RJ, Horowitz MM, Dupont B (2005) Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. Blood 105: 4878 – 4884

Jamieson AM, Isnard P, Dorfman JR, Coles MG, Raulet DH (2004) Turnover and proliferation of NK cells in steady state and lymphopenic conditions. J Immunol 172: 864 – 870

Kim S, Poursine-Laurent J, Truscott SM, Lybarger L, Song YJ, Yang L, French AR, Sunwoo JB, Lemieux S, Hansen TH, Yokoyama WM (2005) Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature 436: 709 – 713

Lanier LL (2005) NK cell recognition. Annu Rev Immunol 23: 225 – 274

Leung W, Iyengar R, Leimig T, Holladay MS, Houston J, Handgretinger R (2005a) Phenotype and function of human natural killer cells purified by using a clinical-scale immunomagnetic method. Cancer Immunol Immunother 54: 389 – 394

Leung W, Iyengar R, Triplett B, Turner V, Behm FG, Holladay MS, Houston J, Handgretinger R (2005b) Comparison of killer Ig-like receptor genotyping and phenotyping for selection of allogeneic blood stem cell donors. J Immunol 174: 6540 – 6545

Leung W, Iyengar R, Turner V, Lang P, Bader P, Conn P, Niethammer D, Handgretinger R (2004) Determinants of antileukemia effects of allogeneic NK cells. J Immunol 172: 644 – 650

Lowe EJ, Turner V, Handgretinger R, Horwitz EM, Benaim E, Hale GA, Woodard P, Leung W (2003) T-cell alloreactivity dominates natural killer cell alloreactivity in minimally T-cell-depleted HLA-non-identical paediatric bone marrow transplantation. Br J Haematol 123: 323 – 326

MacDonald HR (2005) NK cell tolerance: revisiting the central dogma. Nat Immunol 6: 868 – 869

Naumova E, Mihaylova A, Stoitchkov K, Ivanova M, Quin L, Toneva M (2005) Genetic polymorphism of NK receptors and their ligands in melanoma patients: prevalence of inhibitory over activating signals. Cancer Immunol Immunother 54: 172 – 178

Parham P (2005) MHC class I molecules and KIRs in human history, health and survival. Nat Rev Immunol 5: 201 – 214

Prlic M, Blazar BR, Farrar MA, Jameson SC (2003) In vivo survival and homeostatic proliferation of natural killer cells. J Exp Med 197: 967 – 976